Cord blood cells aim to heal Radiation-Damaged lungs
NCT ID NCT07177456
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-stage trial tests whether umbilical cord blood cells can safely treat lung damage caused by radiation therapy for cancer. Ten adults who have not improved with standard care will receive three weekly infusions of these cells. The main goal is to check safety and see if lung damage improves on CT scans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- umbilical cord blood mononuclear cells
- What this could lead to
- If it works, this could point toward a new treatment for lung damage caused by radiation therapy, helping patients breathe easier.
- What could go wrong
- This is a very early, small trial with only 10 people. It is designed mainly to check safety, not yet to prove effectiveness. The treatment may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Ages 18-75 years,with no restriction on gender; 2. History of chest radiotherapy; 3. Diagnosed with grade 2-3 radiation-induced lung injury according to CTCAE 4.0 classification criteria in "Diagnosis and Treatment of Radiation-induced Lung Injury"; 4. Inadequate response to conventional treatment for two weeks, with no relief or progressive worsening of symptoms; 5. Well-controlled tumor for ≥3 months; 6. No significant liver or kidney dysfunction: ALT, AST ≤ 3 times the upper limit of normal, serum Cr and BUN ≤ 2 times the upper limit of normal; 7. Expected survival ≥ 3 months; 8. Informed consent signed voluntarily by the patient; 9. Willing and able to receive treatment and follow-up as required by the protocol, and able to comply with basic treatment as directed by the physician. Exclusion Criteria: 1. Severe cardiac insufficiency (such as NYHA class III or IV), uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥110mmHg); 2. Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis; 3. ECOG score ≥2; 4. Currently participating in or participated in other clinical trials within 4 weeks; 5. History of allergies or known allergy to the study preparation; 6. Patients with psychiatric disorders who cannot cooperate with treatment; (7) Pregnant or lactating women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Radiation-induced lung injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.